Skip to main content
construction release_alert
The Scholars Team is working with OIT to resolve some issues with the Scholars search index
cancel
Journal cover image

Pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants.

Publication ,  Journal Article
Kumar, KR; Ciociola, EC; Skinner, KR; Dixit, GM; Alvarez, S; Benjamin, EK; Faulkner, JC; Greenberg, RG; Clark, RH; Benjamin, DK; Hornik, CP; Lee, JH
Published in: Cardiol Young
January 2025

BACKGROUND: New drugs to target different pathways in pulmonary hypertension has resulted in increased combination therapy, but details of this use in infants are not well described. In this large multicenter database study, we describe the pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants. METHODS: We identified inborn infants discharged home from a Pediatrix neonatal ICU from 1997 to 2020 exposed to inhaled nitric oxide, sildenafil, epoprostenol, or bosentan for greater than two consecutive days. We compared clinical variables and drug utilisation between infants receiving simultaneous combination and monotherapy. We reported each combination's frequency, timing, and duration and graphically represented drug use over time. RESULTS: Of the 7681 infants that met inclusion criteria, 664 (9%) received combination therapy. These infants had a lower median gestational age and birth weight, were more likely to have cardiac and pulmonary anomalies, receive cardiorespiratory support, and had higher in-hospital mortality than those receiving monotherapy. Inhaled nitric oxide and sildenafil were most frequently used, and utilisation of combination and monotherapy for all drugs increased over time. Inhaled nitric oxide and epoprostenol were used in infants with a higher gestational age, earlier postnatal age, and shorter duration than sildenafil and bosentan. Dual therapy with inhaled nitric oxide and sildenafil was the most common combination therapy. CONCLUSION: Our study revealed an increased use of combination pulmonary vasodilator therapy, favouring inhaled nitric oxide and sildenafil, yet with considerable practice variation. Further research is needed to determine the optimal combination, sequence, dosing, and disease-specific indications for combination therapy.

Duke Scholars

Published In

Cardiol Young

DOI

EISSN

1467-1107

Publication Date

January 2025

Volume

35

Issue

1

Start / End Page

93 / 101

Location

England

Related Subject Headings

  • Vasodilator Agents
  • Sildenafil Citrate
  • Retrospective Studies
  • Pharmacoepidemiology
  • Nitric Oxide
  • Male
  • Infant, Newborn
  • Infant
  • Hypertension, Pulmonary
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kumar, K. R., Ciociola, E. C., Skinner, K. R., Dixit, G. M., Alvarez, S., Benjamin, E. K., … Lee, J. H. (2025). Pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants. Cardiol Young, 35(1), 93–101. https://doi.org/10.1017/S1047951124025976
Kumar, Karan R., Elizabeth C. Ciociola, Kayla R. Skinner, Gargi M. Dixit, Sunshine Alvarez, Elijah K. Benjamin, Jeffrey C. Faulkner, et al. “Pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants.Cardiol Young 35, no. 1 (January 2025): 93–101. https://doi.org/10.1017/S1047951124025976.
Kumar KR, Ciociola EC, Skinner KR, Dixit GM, Alvarez S, Benjamin EK, et al. Pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants. Cardiol Young. 2025 Jan;35(1):93–101.
Kumar, Karan R., et al. “Pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants.Cardiol Young, vol. 35, no. 1, Jan. 2025, pp. 93–101. Pubmed, doi:10.1017/S1047951124025976.
Kumar KR, Ciociola EC, Skinner KR, Dixit GM, Alvarez S, Benjamin EK, Faulkner JC, Greenberg RG, Clark RH, Benjamin DK, Hornik CP, Lee JH. Pharmacoepidemiology of combination pulmonary vasodilator therapy in critically ill infants. Cardiol Young. 2025 Jan;35(1):93–101.
Journal cover image

Published In

Cardiol Young

DOI

EISSN

1467-1107

Publication Date

January 2025

Volume

35

Issue

1

Start / End Page

93 / 101

Location

England

Related Subject Headings

  • Vasodilator Agents
  • Sildenafil Citrate
  • Retrospective Studies
  • Pharmacoepidemiology
  • Nitric Oxide
  • Male
  • Infant, Newborn
  • Infant
  • Hypertension, Pulmonary
  • Humans